Navigation Links
Study identifies key molecules in multiple myeloma
Date:10/26/2010

COLUMBUS, Ohio New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

The findings might offer a new strategy for treating this disease and other blood cancers, according to researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) who led the study.

The silenced molecules are called miR-192, miR-194 and miR-215. All of them are microRNAs, a large class of molecules that are master regulators of many important cell processes.

The study, published in the Oct. 19 issue of Cancer Cell, suggests that re-activating these three molecules triggers expression of the P53 tumor suppressor gene. This, in turn, slows the growth and leads to the death of myeloma cells and could provide a new strategy for treating the disease.

"These findings provide a rationale for the further exploration of these microRNAs as a treatment for multiple myeloma, which has few therapeutic options," says principal investigator Dr. Carlo Croce, professor and chair of Molecular Virology, Immunology and Medical Genetics, and director of the Human Cancer Genetics program at the OSUCCC James.

Multiple myeloma is a disorder of white blood cells called plasma cells. More than 20,100 Americans are expected to develop the disease this year and some 10,600 are expected to die from it. Myeloma begins as a benign condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS can live for many years without treatment. Then, for unknown reasons, this benign condition can evolve into multiple myeloma.

Studies investigating the molecular causes of the disease have shown a relationship between P53 and another gene called MDM2. They have also shown that myeloma cells often have healthy (i.e., unmutated) P53 genes but ver
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landenberger Foundation awards grant to Scripps Florida scientist to study HIV
2. Penn study identifies molecular guardian of cells RNA
3. LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension
4. Offshore wind a mixed bag: University of Maryland study
5. Modeling study identifies characteristics of high elk-use areas in western Oregon, Washington
6. Universities receive grants to study climate change decisions
7. Center to study effects of plastics chemicals on childrens health
8. Study of tiny magnets may advance their use in microelectronics
9. BMC receives National Institutes of Health grant to study intrauterine cocaine and substance reslience
10. CRN responds to JAMA fish oil study
11. Singapore scientists first to perform genome-wide study of human stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... with a Star Trek twist, at the U.S. Department ... Determining who needs medical care at the scene ... bent over a victim, checking body temperature, heart rate, ... entire process can take 3-5 minutes per person. ...
... a "Dream Team." Lombardi Comprehensive Cancer Center,s ... and 12 of the nation,s top breast cancer researchers ... Up To Cancer (SU2C) to form a scientific "Dream ... brightest scientists will conduct new breast cancer research with ...
... Rice University researchers today announced that the first ... technology for removing arsenic from drinking water, will ... "Mexico,s debating the adoption of more stringent national ... water, and officials in Guanajuato are looking ahead ...
Cached Biology News:Triage technology with a Star Trek twist 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 3First 'nanorust' field test slated in Mexico 2
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... -- Isagenix International, a leading global health and wellness ... and three Bronze Stevie® Awards at the 2015 Annual ... this month.The American Business Awards ... the U.S. "Winning is a tremendous ... cultivating talent, creating a unified team, and crafting the ...
(Date:7/1/2015)... InferMed , s decision ... augment Elsevier ... suite   Elsevier , a world-leading provider ... today the acquisition of  InferMed , a London ... InferMed,s Arezzo technology supports clinicians in choosing the most appropriate ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer is scheduled to present at the 20th,Annual ... 2007,at 8:30 a.m. Eastern Daylight Time. The conference ...
... the Phase III Clinical Development and ... of THR-100 in Developing Countries, LEUVEN, Belgium, ... biotechnology company focused on vascular disease, today,announced the ... International Limited (Hyderabad, India) for the manufacture of,THR-100, ...
... Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical ... products and high intensity focused ultrasound tumor,therapy systems, today announced ... - China Day. Location: ... ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
... in the Microsart e.motion are sterile-sealed, without protective ... specially designed individual package on a band. ... membrane filter units ensures that they are perfectly ... band guarantees uniform dispensing of the individual membrane ...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Biology Products: